Targeted pharmacological reversal of electrical remodeling after cardioversion—Rationale and design of the Flecainide Short-Long (Flec-SL) trial
- 1 November 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 150 (5) , 899.e1-899.e6
- https://doi.org/10.1016/j.ahj.2005.07.020
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Amiodarone versus Sotalol for Atrial FibrillationNew England Journal of Medicine, 2005
- Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: Results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) studyHeart Rhythm, 2005
- Prevention of atrial fibrillation after cardioversion: results of the PAFAC trialEuropean Heart Journal, 2004
- Suppression of paroxysmal atrial tachyarrhythmias ? results of the SOPAT trialEuropean Heart Journal, 2004
- Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular FibrillationThe Journal of Pharmacology and Experimental Therapeutics, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial FibrillationNew England Journal of Medicine, 2002
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial FibrillationCirculation, 2002
- A Patient with “Atrial Torsades de Pointes”Journal of Cardiovascular Electrophysiology, 2000
- Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine-month follow-up of more than 500 patientsThe American Journal of Cardiology, 1992